Back to search results
NCT06618300

Streamlined Resin Y90 Radiation Segmentectomy for Small HCC

Active, Not Recruiting
Not specifiedAges 18+Observational
UNC Lineberger Comprehensive Cancer Center
~30 participants
Updated 2026-08-13 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The treatment timeline
Measured over 3 days
+1 more outcome measured

Conditions

Hepatocellular Carcinoma (HCC)

Explore related trials

Hepatocellular Carcinoma

NCT06618300

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UNC Hospitals

    Chapel Hill, North Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Hyeon Yu, MD, FSIR · PRINCIPAL_INVESTIGATOR · UNC Department of Radiology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Has focal Hepatocellular Carcinoma and is deemed to benefit from Yttrium-90 radioembolization by the institutional multidisciplinary tumor board

Exclusion

The presence of trans-jugular intrahepatic portosystemic shunt
Total bilirubin level \> 3.0 mg/dL
Serum albumin level \< 2.5 g/dL
Aspartate and alanine aminotransferase levels no greater than five times the normal level
Life expectancy \< 12 weeks
Eastern Cooperative Oncology Group performance status \> 2
Patients with chronic lung disease requiring supplemental oxygen at baseline or baseline SpO2 of \<92%
Patients that have tumors with central anatomical locations close the hepatic hilum or caudate lobe.
Patients with macrovascular invasion on baseline imaging
Known hypersensitivity to iodinated contrast agents or to any component of iodinated contrast agents refractory to standard medications (antihistamines, steroids)
Impaired kidney function (glomerular filtration rate \< 30 as approximated using serum creatinine levels) unless anuric and on dialysis.
Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 48 hours prior to the treatment or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)

What this trial measures

  • The treatment timeline3 days

    The treatment timeline will be measured in days from the date of the initial consultation of the patient in the interventional radiology clinic to the date of the Yttrium-90 (Y90) radioembolization procedure.

  • Cumulative charges and reimbursement3 days

    To observe cumulative charges and reimbursement for streamlined Yttrium-90 (Y90) radioembolization treatment, billing, and reimbursement information will be obtained through the billing department. The costs will be reported in US dollars.